Oral Desensitization to Entecavir: An 11 Step Protocol

An estimated 248 million individuals live with chronic hepatitis B infection worldwide [1]. Chronic hepatitis B infection (CH-B) has a high risk of progression to cirrhosis and hepatocellular carcinoma. Entecavir, a guanosine nucleoside analogue, is often the drug of choice in nucleoside-na ïve patients with CH-B because of its low rate of viral resistance. Resistance to entecavir therapy in nucleoside-naïve patients is approximately 1 percent after five years of treatment [2]. The efficacy and safety of entecavir has been well-studied in different patient populations with CH-B.

Source: Annals of Allergy, Asthma and Immunology - June 21, 2019 Category: Allergy & Immunology Authors: Annamaria Mechtler, Nahla H. Ahmed, Jo Ann Wheeler, Alexei Gonzalez-Estrada Tags: Letters Source Type: research